User profiles for Ulf Börjesson

Ulf Börjesson

Hit Discovery, Discovery Sciences, AstraZeneca
Verified email at astrazeneca.com
Cited by 665

[HTML][HTML] Analysis of a 10-ns molecular dynamics simulation of mouse acetylcholinesterase

K Tai, T Shen, U Börjesson, M Philippopoulos… - Biophysical journal, 2001 - cell.com
A 10-ns molecular dynamics simulation of mouse acetylcholinesterase was analyzed, with
special attention paid to the fluctuation in the width of the gorge and opening events of the …

Explicit-solvent molecular dynamics simulation at constant Methodology and application to small amines

U Börjesson, PH Hünenberger - The Journal of Chemical Physics, 2001 - pubs.aip.org
A method is developed for performing classical explicit-solvent molecular dynamics (MD)
simulations at constant p H , where the protonation state of each ionizable (titratable) group in …

Chemogenetics defines a short-chain fatty acid receptor gut–brain axis

N Barki, D Bolognini, U Börjesson, L Jenkins, J Riddell… - Elife, 2022 - elifesciences.org
Volatile small molecules, including the short-chain fatty acids (SCFAs), acetate and propionate,
released by the gut microbiota from the catabolism of nondigestible starches, can act in a …

Discovery and optimization of the first ATP competitive type-III c-MET inhibitor

IN Michaelides, GW Collie, U Börjesson… - Journal of Medicinal …, 2023 - ACS Publications
Recent clinical reports have highlighted the need for wild-type (WT) and mutant dual inhibitors
of c-MET kinase for the treatment of cancer. We report herein a novel chemical series of …

[HTML][HTML] Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides

…, C Bardelle, P Harper, WD Hong, U Börjesson… - Nature …, 2019 - nature.com
Nematodes causing lymphatic filariasis and onchocerciasis rely on their bacterial endosymbiont,
Wolbachia, for survival and fecundity, making Wolbachia a promising therapeutic target…

Discovery of AZD8154, a dual PI3Kγδ inhibitor for the treatment of asthma

…, K Bjorhall, P Bold, M Brulls, U Borjesson… - Journal of Medicinal …, 2021 - ACS Publications
Starting from our previously described PI3Kγ inhibitors, we describe the exploration of
structure–activity relationships that led to the discovery of highly potent dual PI3Kγδ inhibitors. We …

Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo Evaluation in an MTAP Null Xenograft Model

C De Fusco, M Schimpl, U Borjesson… - Journal of Medicinal …, 2021 - ACS Publications
MAT2a is a methionine adenosyltransferase that synthesizes the essential metabolite S-adenosylmethionine
(SAM) from methionine and ATP. Tumors bearing the co-deletion of p16 …

Fragment screening at AstraZeneca: developing the next generation biophysics fragment set

SCC Lucas, U Börjesson, MJ Bostock, J Cuff… - RSC Medicinal …, 2022 - pubs.rsc.org
Fragment based drug discovery is a critical part of the lead generation toolbox and relies
heavily on a readily available, high quality fragment library. Over years of use, the AstraZeneca …

pH-dependent stability of a decalysine α-helix studied by explicit-solvent molecular dynamics simulations at constant pH

U Börjesson, PH Hünenberger - The Journal of Physical Chemistry …, 2004 - ACS Publications
The acidostat method previously developed for performing explicit-solvent molecular dynamics
simulations at constant pH (J. Chem. Phys. 2001, 114, 9706) is applied to polyfunctional …

Patient based 'burden‐of‐illness' in Swedish primary health care. Applying the Johns Hopkins ACG case‐mix system in a retrospective study of electronic patient …

L Carlsson, U Börjesson… - The International journal of …, 2002 - Wiley Online Library
Patients from one municipality in Sweden utilizing primary health care (PHC) during 1998
and 1999 have been categorized into 81 groups. The groups show each patient's own case‐…